title: Management of hepatitis B in special patient populations.
abstract: Hepatitis B virus is a common cause of acute liver failure. It can be especially problematic in patients coinfected with hepatitis C, hepatitis D or human immunodeficiency virus. In addition, immunosuppression-associated hepatitis B reactivation is being increasingly recognized following chemotherapy, biologic therapy, and organ transplantation. This article highlights treatment options in these special populations.
authors.affiliation: Dumont-UCLA Liver Transplant Center, David Geffen School of Medicine at University of California Los Angeles, 90095, USA.
authors.forename: Hank S
authors.initials: HS
authors.lastname: Wang
authors.forename: Steven-Huy B
authors.initials: SH
authors.lastname: Han
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D016027:Heart Transplantation / Q000276:immunology; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D003699:Hepatitis D / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016898:Interferon-alpha / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D017114:Liver Failure, Acute / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D055502:Secondary Prevention
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha